Since founding, with the vision of “becoming a global leader in the field of regenerative medicine,” we at SanBio have been engaged in the R&D of regenerative cell therapies targeting diseases for which there currently exists no cure.
We are one of the few companies in the world that are exploring ways to regenerate brain function, a feat considered impossible for over a century. We believe that we are only a step away from obtaining marketing approval for and launching our SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan, our topmost priority at the moment, which will be the world’s first for a regenerative medicine product for regenerating brain function.
If we obtain marketing approval for and launch the regenerative medicine product, the world’s first for restoring brain function, we can contribute to improving the quality of life for patients, including those suffering from motor paralysis caused by chronic traumatic brain injury or chronic ischemic stroke, for instance, by helping them regain their ability to walk and perform other physical tasks and to talk.
The situation of the world is changing constantly across all areas, including the natural environment, economy, and technology. Amid these changes, we aim to realize “a society where everyone can achieve lifelong health and lead a prosperous and fulfilling life,” and in our endeavors to realize this goal, we will maintain sustainable growth.
Our mission is to provide value to patients and all other stakeholders through the development of regenerative medicine, and we at SanBio will continue doing our utmost to fulfill this mission.
We kindly ask for your continued support.
April 25, 2024
Keita Mori, CEO
